1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsMultiple deadlines: September 5, 2024; January 5, 2025; April 5, 2025; September 5, 2025. Final close date was September 6, 2025. This is the PHS 2024-2 omnibus solicitation (PA-24-245) — not FDA-specific but a joint NIH/CDC/FDA solicitation.
Small Business Innovation Research (SBIR) program (FDA) is sponsored by Food and Drug Administration (FDA). The FDA's SBIR program encourages domestic small businesses to engage in research and development with the potential for commercialization of medical devices.
Get alerted about grants like this
Save a search for “Food and Drug Administration (FDA)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) Solicitation Number: PA-27-100 Solicitation Status: Open NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date.
For this reason, you should use the agency link listed below which will take you directly to the appropriate agency server where you can read the official version of this solicitation and download the appropriate forms and rules.
View Official Solicitation September 5, 2026; January 5, 2027; April 5, 2027 The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs (also known as America's Seed Fund) are major sources of early-stage funding for U.S. technology development and commercialization.
By providing awards to SBCs, the SBIR program supports the commercialization of innovative technologies and strengthens U.S. small businesses.
The National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA) use these programs to help US-owned and operated small businesses develop promising technologies and products that support their missions to enhance the health and well-being of all Americans. NIH, CDC and FDA are required to set-aside 3. 2% of their extramural research budget for the SBIR program.
This NOFO supports a small business to do the research and development (R&D) needed to develop a commercial product. The small business should propose to do the majority of the research or analytical effort, and the Program Director/Principal investigator (PD/PI) should be primarily employed by the small business. SBIR projects allow for limited research or analytical effort to be done by research partners or consultants.
See eligibility requirements in Section III. Small businesses should apply to STTR NOFO PA-27-102 if the project depends on a formal collaboration with a nonprofit research institution, such as a university. STTRs also allow the PD/PI of the project to be primarily employed by either the small business or nonprofit research partner.
In both the SBIR and STTR programs, the award goes to the small business. Applicants are strongly encouraged to contact program staff prior to applying to help choose the best funding opportunity for their project. The SBIR Program supports projects through multiple phases: Phase I: Establish the technical merit and feasibility of the proposed R&D.
Phase II: Continue R&D to advance toward commercialization. After Phase II, NIH expects small business concerns (SBCs) to fully commercialize the product or technology using non-SBIR/STTR funds (federal or non-federal). This NOFO accepts SBIR Phase I, Phase II, Direct to Phase II (NIH only), and Fast-Track (NIH only), grant applications from eligible United States SBCs.
NIH Fast-Track: The NIH Fast-Track allows both Phase I and Phase II of a project to be submitted and reviewed together as one application to reduce or eliminate the funding gap between phases. NIH Direct to Phase II: Small businesses that have already demonstrated scientific and technical merit and feasibility but have not received a Phase I SBIR or STTR for that project, can apply for a Direct to Phase II award.
The NIH will accept Direct to Phase II applications regardless of the funding source for the work on which the proposed Phase II research is based. Direct to Phase II awards should be submitted as "New" applications and not continuations ("Renewal") of Phase I SBIR or STTR projects.
Small businesses that are eligible to submit a Phase II application for projects that were supported with a Phase I SBIR or STTR award are expected to submit the regular Phase II application as a "Renewal" application based on the awarded Phase I SBIR or STTR project. Only one Phase II application may be awarded for a specific project supported by a Phase I award.
SBIR Phase IIB Strategic Breakthrough grant applications should be submitted to PA-27-101. Scientific and Technical Scope Applications from eligible United States SBCs should propose a feasibility and/or R&D study that contributes to the missions of any NIH, CDC or FDA components participating in this NOFO.
See NIH Institutes, Centers, and Offices and Small Business Funding Considerations and Contacts for Institute, Center, and Office (ICO) specific missions, interest areas, funding priorities, and funding considerations. See the NIH Director's Statement of Priorities (https://www. nih.
gov/about-nih/nih-director/statements/advancing-nihs-mission-through-unified-strategy), entitled "Advancing NIH's Mission Through a Unified Strategy," the CDC Director's Statement of Priorities (https://www. cdc. gov/about/cdc/index.
html), entitled "CDC Priorities," and the FDA's Mission Statement (https://www. fda. gov/about-fda/what-we-do#mission), entitled "FDA Mission."
Staff within the NIH's Center for Scientific Review (CSR) office, the single receiving point for all NIH grant applications, will assign all applications to the most appropriate participating component. Applicants are not required to identify a potential awarding component prior to submission of the application but may request one on the Assignment Request Form.
Applicants are encouraged to contact the appropriate NIH Institute, Center, or Office they believe is the best fit for their proposed research prior to submission. Further information about the SBIR and STTR programs can be found at https://seed. nih.
gov. Frequently asked questions are available to assist applicants and can answer many basic questions about the program. Investigators proposing NIH-defined clinical trials may refer to the Research Methods Resources website for information about developing statistical methods and study designs.
Applications Not Responsive to this NOFO The following types of applications are not responsive to this NOFO and will not be reviewed: Applications to this Parent NOFO may include clinical trial(s).
However, the following Institutes and Centers DO NOT ACCEPT clinical trials under this NOFO and applications that propose a clinical trial and only align with the mission of one of the following components are not responsive to this NOFO and will not be reviewed: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) National Institute of Dental and Craniofacial Research (NIDCR) National Center for Advancing Translational Sciences (NCATS) Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs (ORIP) All participating components of the Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER/FDA) Center for Drug Evaluation and Research (CDER/FDA) Human Foods Program (HFP/FDA) Center for Devices and Radiological Health (CDRH/FDA) Center for Veterinary Medicine (CVM/FDA)
Based on current listing details, eligibility includes: Small businesses with no more than 500 employees, majority ownership by U.S. citizens or another U.S.-based small business, and all work performed in the U.S. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Generally up to $600K for Phase I and $3.5M for Phase II Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Past winners and funding trends for this program
PAR-24-251: Animal and Veterinary Innovation Centers (U18) is sponsored by Food and Drug Administration (FDA), Center for Veterinary Medicine (CVM). The FDA's Center for Veterinary Medicine (CVM) is seeking applications for Animal and Veterinary Innovation Centers (AVICs) to address critical unmet needs impacting animal and human health. These cooperative agreements will establish long-term partnerships with academic research institutions to advance regulatory science and the development of innovative animal products, focusing on areas like Highly Pathogenic Avian Influenza (HPAI), intentional genomic alterations in animals, and unmet veterinary medical needs in minor and major species.
AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program; Request for Information is sponsored by Food and Drug Administration (FDA). The Food and Drug Administration (FDA) is issuing this request for information to solicit input on a proposed pilot program to assess how artificial intelligence (AI)-enabled technologies can improve efficiency, speed, and quality of decision-making in early phase clinical trial…
Animal and Veterinary Innovation Centers (AVICs) is a grant from the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) that funds long-term cooperative research partnerships with academic institutions to address priority animal and veterinary health areas. Research priorities include developing interventions to prevent, control, or eliminate Highly Pathogenic Avian Influenza (HPAI) in animals; advancing intentional genomic alterations in animals to support agricultural resilience and food security; and developing products for minor species or minor uses in major species with unmet veterinary medical needs. Up to five cooperative agreements are expected under this opportunity (FON: PAR-24-251). Eligible applicants are public or private academic research institutions. The application deadline is June 12, 2026.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.